The Latest News from All Areas of Deals
Latham & Watkins Advises Sobi on Strategic Licensing and Collaboration Agreement with Apellis Pharmaceuticals Inc
Sobi, a specialised international biopharmaceutical company transforming the lives of people with rare diseases, and Apellis Pharmaceuticals, Inc., a clinical-stage…
Linklaters advises underwriters for the European Commission’s largest-ever social bond
At €17 billion, the deal is the largest amount ever borrowed by the European Commission The European Commission’s first Covid-related…
Linklaters advises The Carlyle Group on its investment in Calastone
Linklaters has advised The Carlyle Group on its investment in Calastone, the largest global funds network. The agreement sees The Carlyle…
Latham & Watkins Advises CONSOL Energy Inc. in its US$34.4 Million Acquisition of the Remaining Public Stake in CONSOL Coal Resources LP
CONSOL Energy Inc. (NYSE: CEIX) (CEIX) and CONSOL Coal Resources LP (NYSE: CCR) (CCR) have announced that they have entered…
Latham & Watkins Advises Underwriters in Foghorn Therapeutics’ IPO
Foghorn Therapeutics Inc., a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies…
Latham & Watkins Advises North Branch Capital on Inaugural Fund Formation
North Branch Capital (North Branch) has announced the final close of its inaugural fund, North Branch Capital Fund I, L.P.…
